Proactive Investors - Run By Investors For Investors

Sareum Holdings investors receive update on progress of cancer drug

SRA737 is a checkpoint kinase-1 inhibitor, one of a new breed of treatments
Sareum Holdings investors receive update on progress of cancer drug
The clinical trials appear to be progressing well

Investors in Sareum Holdings PLC (LON:SAR) received an update on the company’s most advanced drugs candidate via Sierra Oncology (NASDAQ:SRRA), the NASDAQ-listed group with which Sareum has a licensing deal.

SRA737 is a checkpoint kinase-1 (Chk1) inhibitor, one of a new breed of cancer treatments, and is currently Phase I/II trials targeting various strains of the killer disease.

READ: Sareum Holdings pleased as Sierra Oncology advances cancer drug trial

It is being tested as a single therapy, in combination with a low-dose chemotherapy called gemcitabine, and in harness with a PARP inhibitor, which helps cells repair themselves.

Sierra in its update said it further refined its single therapy study to focus on high-grade serous ovarian cancer (HGSOC), “supported by emerging data in the field that provides clinical validation for Chk1 inhibition in this indication”.

Priority to ovarian cancer patients 

“Accordingly, we are prioritising the enrolment of approximately 65 genetically defined HGSOC patients into this trial, while continuing to enrol patients into the trial's other indications, although with lower priority," added Dr Nick Glover, Sierra’s chief executive.

"However, given that this amendment will require time to operationalise, we anticipate preliminary data from our monotherapy trial will be reported in the first half of 2019."

The American company is also planning to give priority to ovarian cancer patients as it recruits for its trial deploying SRA737 alongside the low-dose chemo.

In the Phase II expansion portion of the trial, which is recruiting 80 patients, 20 will be HGSOC sufferers, replacing an originally-proposed cohort of urothelial cancer patients.

Preliminary data from this trial is now expected in the first half of 2019.

Derren Nathan, of small-cap broker Hybridan, said: "We believe that the change in the trial designs to prioritise patients with high grade serous ovarian cancer (HGSOC) optimises the chance of a positive outcome, given the validation of this target evidenced by Lily’s Prexasertib data released earlier this year.

"Pre-clinical data by Sierra is also supportive of this rationale. We therefore believe the trade-off between trial optimisation and slightly extended timeline, is a decision well made."

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
June 27 2018
Ridinilazole is a possible treatment for C. Difficile and Summit hopes to kick off a phase III trial in the first quarter of 2019

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use